Skip to main content
    R

    Replimune Group Inc (REPL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.41
    -0.48 (-2.19%)

    Market Cap: $2.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Replimune Group Inc (REPL) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    Replimune Group reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was -$313.94M, operating cash flow was -$280.34M and free cash flow was -$284.57M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$57.12M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $319.92M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$0N/AN/AN/AN/A
    Mar 2025$0N/AN/AN/AN/A
    Mar 2024$0N/AN/AN/AN/A
    Mar 2023$0N/AN/AN/AN/A
    Mar 2022$0N/AN/AN/AN/A
    Mar 2021$0N/AN/AN/AN/A
    Mar 2020$0N/AN/AN/AN/A
    Mar 2019$0N/AN/AN/AN/A
    Mar 2018$0N/AN/AN/AN/A
    Mar 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Cost of revenue$0$0$0$0$0$0$0$0$0$122.00K
    Gross profit$0$0$0$0$0$0$0$0$0-$122.00K
    Research and development$221.18M$189.45M$173.04M$126.53M$79.55M$56.75M$38.76M$22.17M$13.52M$6.94M
    Operating income-$319.92M-$261.63M-$234.77M-$177.08M-$118.31M-$79.95M-$56.20M-$30.95M-$19.23M-$9.65M
    Net income-$313.94M-$247.30M-$215.79M-$174.28M-$118.04M-$80.87M-$55.71M-$30.83M-$19.70M-$7.70M
    EBITDA-$316.04MN/AN/AN/A-$111.84M-$74.73MN/AN/AN/A-$8.08M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$1.47M$0$0$0$4.04M$0
    Gross profit$0$0N/A$0$0$0-$848.00K$0$0$0$3.39M$0
    Operating income-$56.28M-$68.25M-$73.34M-$71.87M-$84.29M-$90.42M-$79.33M-$66.02M-$58.92M-$57.37M-$58.75M-$56.54M
    Net income-$57.12M-$69.77M-$73.22M-$70.93M-$83.10M-$86.69M-$74.13M-$66.34M-$53.05M-$53.77M-$55.08M-$51.12M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded total debt of $87.35M by $121.67M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$332.39M$551.33M$487.72M$646.59M$461.19M$543.10M$234.10M$154.33M$65.15M$22.82M
    Current assets$279.12M$495.88M$433.67M$592.60M$403.98M$483.75M$174.25M$140.98M$64.70M$22.40M
    Cash and equivalents$209.02M$111.12M$74.46M$146.59M$105.95M$182.52M$59.50M$25.70M$17.58M$20.59M
    Total liabilities$166.23M$135.49M$113.21M$91.30M$49.96M$44.37M$50.38M$16.47M$6.86M$34.33M
    Short-term debt$4.04M$3.98M$3.88M$3.76M$3.63M$3.46M$3.28MN/AN/AN/A
    Long-term debt$83.31M$46.38M$44.81M$28.65MN/AN/A$9.80M$0N/AN/A
    Shareholder equity$166.16M$415.84M$374.51M$555.29M$411.23M$498.73M$183.72M$137.86M-$28.07M-$11.52M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$373.94M$252.45M$332.39M$333.59M$389.45M$469.51M$551.33M$603.63M$498.20M$534.97M$487.72M$532.93M
    Total liabilities$169.16M$146.80M$166.23M$123.05M$126.11M$132.79M$135.49M$121.25M$116.74M$108.51M$113.21M$111.39M
    Cash and equivalents$307.83M$185.36M$209.02M$122.95M$102.30M$97.37M$111.12M$172.25M$113.49M$151.66M$74.46M$97.67M
    Shareholder equity$204.78M$105.64M$166.16M$210.54M$263.34M$336.71M$415.84M$482.37M$381.46M$426.45M$374.51M$421.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$280.34M-$192.25M-$185.47M-$128.05M-$82.18M-$61.39M-$60.55M-$25.38M-$16.01M-$7.08M
    Capital expenditures$4.22M$6.69M$5.66M$2.27M$2.34M$2.39M$6.54M$2.60M$136.00K$238.00K
    Free cash flow-$284.57M-$198.94M-$191.13M-$130.32M-$84.52M-$63.78M-$67.09M-$27.98M-$16.15M-$7.32M
    Dividends paidN/AN/AN/AN/AN/A$91.65M$28.14MN/AN/AN/A
    Share repurchasesN/AN/AN/AN/AN/A$100.00K$355.00K$2.16M$0N/A
    Investing cash flow$310.84M-$23.80M$97.20M-$142.50M-$1.81M-$188.78M-$5.23M-$65.94M-$44.05M-$238.00K
    Financing cash flow$66.29M$252.40M$16.28M$311.30M$6.60M$372.46M$100.17M$101.39M$54.75M$15.00M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$47.70M-$75.73M-$56.16M-$65.95M-$81.21M-$77.02M-$53.73M-$50.71M-$38.64M-$49.17M-$46.17M-$47.12M
    Capital expenditures$77.00K$6.00K$5.00K$135.00K$1.34M$2.74M$1.13M$1.80M$2.08M$1.67M$1.74M$1.72M
    Free cash flow-$47.78M-$75.73M-$56.17M-$66.09M-$82.56M-$79.76M-$54.87M-$52.51M-$40.72M-$50.84M-$47.91M-$48.84M
    Last 12 quarters

    Frequently Asked Questions About REPL

    What is Replimune Group's annual revenue?

    Replimune Group reported revenue of $0 for the fiscal year ended Mar 31, 2026.

    Is Replimune Group profitable?

    No. Replimune Group reported net income of -$313.94M for the fiscal year ended Mar 31, 2026.

    How much free cash flow does REPL generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$280.34M minus capital expenditures of $4.22M produced free cash flow of -$284.57M.

    How much debt does Replimune Group have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of $83.31M, short-term debt of $4.04M and cash and equivalents of $209.02M.